RxDoctor Payments Data

Sherrie Jenkins

Family · Powell, TNNPI 1316185895

Payments from drug & device makers

$3,055in general payments, 2019–2025

Across 168 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$286
  • Johnson & Johnson$243
  • Ferring Pharmaceuticals Inc.$129
  • Merck$107
  • Takeda Pharmaceuticals U.S.A., Inc.$98
  • plus $800 from 20 others

What the payments were for

  • Food & beverage$2,95497%
  • Education$1013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,055 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$58,140
Medicare patients
435
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$45,380
LinzessLinaclotide50$44,367
TrulancePlecanatide14$12,331
Colestipol Hcl89$11,203
Mesalamine16$6,564
Dexlansoprazole DrDexlansoprazole16$6,388
Famotidine500$5,452
MovantikNaloxegol Oxalate12$5,414
Lubiprostone27$4,735
Mesalamine ErMesalamine12$4,385
Sucralfate47$3,655
Pantoprazole Sodium258$3,007
Esomeprazole Magnesium62$2,424
Omeprazole209$2,128
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates29$1,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,393$89,74765 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$286$12,33114 claims
Redhill Biopharma Inc.Movantik$15$5,41412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Powell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →